Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
04/2012
04/26/2012US20120100179 Use of micrornas to control virus helper nucleic acids
04/26/2012US20120100178 Compositions And Methods For Treatment Of Microbial Infections
04/26/2012US20120100177 Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof
04/26/2012US20120100176 Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
04/26/2012US20120100174 Composition comprising sortase anchored surface proteins of streptococcus uberis
04/26/2012US20120100173 Methods for preparing and using multichaperone-antigen complexes
04/26/2012US20120100172 Immunogenic streptococcus pneumoniae peptides and peptide-multimers
04/26/2012US20120100171 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
04/26/2012US20120100170 Compositions and methods for the treatment of hepatitis c
04/26/2012US20120100169 Vaccine for Cervical Cancer
04/26/2012US20120100168 Cyclovirus and methods of use
04/26/2012US20120100167 Allergen peptide fragments and use thereof for treatment of dust mite allergies
04/26/2012US20120100165 Drug transporter, and adjuvant and vaccine each utilizing same
04/26/2012US20120100164 Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
04/26/2012US20120100163 Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
04/26/2012US20120100161 Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy
04/26/2012US20120100160 Methods for Inducing Mixed Chimerism
04/26/2012US20120100159 Anti-tat226 antibodies and immunoconjugates
04/26/2012US20120100158 Anti ceacam1 antibodies and methods of using same
04/26/2012US20120100157 Biomarker and Method for Predicting Sensitivity to MET Inhibitors
04/26/2012US20120100156 Therapeutic Agent
04/26/2012US20120100155 Pharmaceutical agent
04/26/2012US20120100154 Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
04/26/2012US20120100153 Stable and soluble antibodies
04/26/2012US20120100152 Anti-human cd52 immunoglobulins
04/26/2012US20120100151 Antibodies or Fragments Thereof Directed Against a Staphylococcus Aureus Epitope of ISAA or ISAB
04/26/2012US20120100150 Influenza Hemagglutinin-Specific Monoclonal Antibodies for Preventing and Treating Influenza Virus Infection
04/26/2012US20120100149 Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent
04/26/2012US20120100148 Anti-ferroportin 1 monoclonal antibodies and uses thereof
04/26/2012US20120100147 Novel antibodies and their uses in therapeutic and diagnostic methods
04/26/2012US20120100146 Nucleotide and amino acid sequences relating to respiratory diseases and obesity
04/26/2012US20120100145 Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
04/26/2012US20120100144 Biomarker and Treatment for Cancer
04/26/2012US20120100143 Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
04/26/2012US20120100142 Monoclonal antibodies to influenza h1n1 virus uses thereof
04/26/2012US20120100141 Drug fusions and conjugates
04/26/2012US20120100140 Stabilized fc polypeptides with reduced effector function and methods of use
04/26/2012US20120100139 CD86 Antagonist Multi-Target Binding Proteins
04/26/2012US20120100138 The use of inhibitors of bruton's tyrosine kinase (btk)
04/26/2012US20120100137 Immunoglobulins
04/26/2012US20120100136 Methods for treating or preventing ophthalmological diseases
04/26/2012US20120100135 Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
04/26/2012US20120100134 Genetic variants in angiogenesis pathway associated with clinical outcome
04/26/2012US20120100133 Use of anti-cd20 antibody for treating primary intraocular lymphoma
04/26/2012US20120100132 Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof
04/26/2012US20120100131 Method for treatment of blood tumor using anti-tim-3 antibody
04/26/2012US20120100130 Novel Receptor Hetero-Dimers/-Oligomers
04/26/2012US20120100129 N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders
04/26/2012US20120100103 In situ forming hydrogel and biomedical use thereof
04/26/2012US20120100102 Cancer vaccine
04/26/2012US20120100101 Ctla-4 antibody dosage escalation regimens
04/26/2012US20120100074 Humanized antibodies against light and uses thereof
04/26/2012US20120100069 B-Lymphocyte Targeting Agents for Use in a Method for the Treatment of a Disease
04/26/2012US20120100068 Anti-CD74 Immunoconjugates and Methods of Use
04/26/2012US20120097565 Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
04/26/2012DE202012101197U1 Glykoantigene mit Kohlenhydratdeterminanten Glykoantigene with carbohydrate determinants
04/26/2012CA2852978A1 Methods for the prevention and/or treatment of memory impairment
04/26/2012CA2852904A1 Assays, methods and kits for predicting renal disease and personalized treatment strategies
04/26/2012CA2849391A1 Chlamydia antigens and uses thereof
04/26/2012CA2815422A1 Antigen-specific, tolerance-inducing microparticles and uses thereof
04/26/2012CA2815125A1 Her2 dna vaccine as adjunct treatment for cancers in companion animals
04/26/2012CA2815102A1 Wdhd1 peptides and vaccines including the same
04/26/2012CA2815100A1 C18orf54 peptides and vaccines including the same
04/26/2012CA2815080A1 Anti-folate receptor alpha antibody glycoforms
04/26/2012CA2815046A1 Human antibodies and specific binding sequences thereof for use in neurological disease
04/26/2012CA2815041A1 Antibodies
04/26/2012CA2815030A1 Selective targeting of the cd40l/mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
04/26/2012CA2814373A1 Identification of antibodies specific for lyssaviruses and methods of their use
04/26/2012CA2813796A1 Erbb3 binding antibody
04/26/2012CA2811075A1 Method of storing a vaccine containing an aluminum adjuvant
04/25/2012EP2444499A2 Amino acid substituted molecules
04/25/2012EP2444492A1 Chicken-derived anti-lox-1 antibody
04/25/2012EP2444423A1 Fc variants with altered binding to FcRn
04/25/2012EP2444421A1 P-Cadherin antibodies
04/25/2012EP2444420A1 P-Cadherin antibodies
04/25/2012EP2444419A1 P-Cadherin antibodies
04/25/2012EP2444418A2 IL-1 Family Variants
04/25/2012EP2444414A1 Peptidic antigen that induces antibody recognizing three-dimensional structure of hiv and method for synthesizing same
04/25/2012EP2444409A2 Compositions and methods for the treatment of immune related diseases
04/25/2012EP2444104A2 Treatment of multiple sclerosis (MS) with campath-1H
04/25/2012EP2444103A1 Vaccine for cervical cancer
04/25/2012EP2444101A1 Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
04/25/2012EP2444100A2 Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
04/25/2012EP2444099A1 Antibodies and related molecules that bind to 161P2F10B proteins
04/25/2012EP2443232A2 System for the heterologous expression of a viral protein in a ciliate host cell
04/25/2012EP2443155A1 Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
04/25/2012EP2443150A2 Anti-vegf antibodies and their uses
04/25/2012EP2443149A1 Bace1 inhibitory antibodies
04/25/2012EP2443147A1 Hla-g alpha 1 multimers and pharmaceutical uses thereof
04/25/2012EP2443138A1 An antigenic peptide derived from influenza virus and a method for selecting anti-influenza virus antibody
04/25/2012EP2442829A2 Structured viral peptide compositions and methods of use
04/25/2012EP2442828A1 Novel manner of administering allergen in allergen specific immunotherapy
04/25/2012EP2442827A1 Nanoemulsion vaccines
04/25/2012EP2442826A1 Influenza vaccine, composition, and methods of use
04/25/2012EP2442825A1 Method for the purification of protein complexes
04/25/2012EP2442820A1 Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders
04/25/2012EP2442798A1 Lyophilized formulations for small modular immunopharmaceuticals
04/25/2012EP2428216A9 Methods of treating cancer using IL-21 and monoclonal antibody therapy
04/25/2012EP2245062B1 Methods of treating bone-loss disorders using a gm-csf antagonist
04/25/2012EP2146727B1 High viscosity macromolecular compositions for treating ocular conditions
1 ... 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 ... 1823